Literature DB >> 24297689

High prevalence of occult pulmonary venous hypertension revealed by fluid challenge in pulmonary hypertension.

Ivan M Robbins1, Anna R Hemnes, Meredith E Pugh, Evan L Brittain, David X Zhao, Robert N Piana, Pete P Fong, John H Newman.   

Abstract

BACKGROUND: Determining the cause for pulmonary hypertension is difficult in many patients. Pulmonary arterial hypertension (PAH) is differentiated from pulmonary venous hypertension (PVH) by a wedge pressure (PWP)>15 mm Hg in PVH. Patients undergoing right heart catheterization for evaluation of pulmonary hypertension may be dehydrated and have reduced intravascular volume, potentially leading to a falsely low measurement of PWP and an erroneous diagnosis of PAH. We hypothesized that a fluid challenge during right heart catheterization would identify occult pulmonary venous hypertension (OPVH). METHODS AND
RESULTS: We reviewed the results of patients undergoing fluid challenge in our pulmonary hypertension database from 2004 to 2011. Baseline hemodynamics were obtained and repeated after infusion of 0.5 L of normal saline for 5 to 10 minutes. Patients were categorized as OPVH if PWP increased to >15 mm Hg after fluid challenge. Baseline hemodynamics in 207 patients met criteria for PAH. After fluid challenge, 46 patients (22.2%) developed a PWP>15 mm Hg and were reclassified as OPVH. Patients with OPVH had a greater increase in PWP compared with patients with PAH, P<0.001, and their demographics and comorbid illnesses were similar to patients with PVH. There were no adverse events related to fluid challenge.
CONCLUSIONS: Fluid challenge at the time of right heart catheterization is easily performed, safe, and identifies a large group of patients diagnosed initially with PAH, but for whom OPVH contributes to pulmonary hypertension. These results have implications for therapeutic trials in PAH and support the routine use of fluid challenge during right heart catheterization in patients with risk factors for PVH.

Entities:  

Keywords:  hemodynamics; hypertension, pulmonary; pulmonary arterial hypertension; pulmonary heart disease

Mesh:

Year:  2013        PMID: 24297689      PMCID: PMC3934572          DOI: 10.1161/CIRCHEARTFAILURE.113.000468

Source DB:  PubMed          Journal:  Circ Heart Fail        ISSN: 1941-3289            Impact factor:   8.790


  21 in total

1.  Occult constrictive pericardial disease. Diagnosis by rapid volume expansion and correction by pericardiectomy.

Authors:  C A Bush; J M Stang; C F Wooley; J W Kilman
Journal:  Circulation       Date:  1977-12       Impact factor: 29.690

2.  Tezosentan in patients with acute heart failure: design of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Study (VERITAS).

Authors:  John R Teerlink; John J V McMurray; Robert C Bourge; John G F Cleland; Gadi Cotter; Guillaume Jondeau; Henry Krum; Marco Metra; Christopher M O'Connor; John D Parker; Guillermo Torre-Amione; Dirk J Van Veldhuisen; Aline Frey; Maurizio Rainisio; Isaac Kobrin
Journal:  Am Heart J       Date:  2005-07       Impact factor: 4.749

3.  The estimation of oxygen consumption.

Authors:  C G LaFarge; O S Miettinen
Journal:  Cardiovasc Res       Date:  1970-01       Impact factor: 10.787

4.  A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST).

Authors:  R M Califf; K F Adams; W J McKenna; M Gheorghiade; B F Uretsky; S E McNulty; H Darius; K Schulman; F Zannad; E Handberg-Thurmond; F E Harrell; W Wheeler; J Soler-Soler; K Swedberg
Journal:  Am Heart J       Date:  1997-07       Impact factor: 4.749

5.  High prevalence of occult left heart disease in scleroderma-pulmonary hypertension.

Authors:  Benjamin D Fox; Avi Shimony; David Langleben; Andrew Hirsch; Lawrence Rudski; Robert Schlesinger; Mark J Eisenberg; Dominique Joyal; Marie Hudson; Kim Boutet; Alexandrina Serban; Ariel Masetto; Murray Baron
Journal:  Eur Respir J       Date:  2012-12-20       Impact factor: 16.671

6.  Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines.

Authors:  Michael McGoon; David Gutterman; Virginia Steen; Robin Barst; Douglas C McCrory; Terry A Fortin; James E Loyd
Journal:  Chest       Date:  2004-07       Impact factor: 9.410

7.  Preoperative pulmonary hemodynamics and early mortality after orthotopic cardiac transplantation: the Pittsburgh experience.

Authors:  S Murali; R L Kormos; B F Uretsky; D Schechter; P S Reddy; B G Denys; J M Armitage; R L Hardesty; B P Griffith
Journal:  Am Heart J       Date:  1993-10       Impact factor: 4.749

8.  Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial.

Authors:  Inder Anand; John McMurray; Jay N Cohn; Marvin A Konstam; Thomas Notter; Kurt Quitzau; Frank Ruschitzka; Thomas F Lüscher
Journal:  Lancet       Date:  2004 Jul 24-30       Impact factor: 79.321

9.  Pulmonary vascular lesions occurring in patients with chronic major vessel thromboembolic pulmonary hypertension.

Authors:  K M Moser; C M Bloor
Journal:  Chest       Date:  1993-03       Impact factor: 9.410

10.  Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension.

Authors:  Gregory D Lewis; Ravi Shah; Khurram Shahzad; Janice M Camuso; Paul P Pappagianopoulos; Judy Hung; Ahmed Tawakol; Robert E Gerszten; David M Systrom; Kenneth D Bloch; Marc J Semigran
Journal:  Circulation       Date:  2007-09-04       Impact factor: 29.690

View more
  48 in total

Review 1.  Heart failure with preserved ejection fraction: mechanisms, clinical features, and therapies.

Authors:  Kavita Sharma; David A Kass
Journal:  Circ Res       Date:  2014-06-20       Impact factor: 17.367

2.  Effect of acute arteriolar vasodilation on capacitance and resistance in pulmonary arterial hypertension.

Authors:  John H Newman; Evan L Brittain; Ivan M Robbins; Anna R Hemnes
Journal:  Chest       Date:  2015-04       Impact factor: 9.410

3.  Variability in hemodynamic evaluation of pulmonary hypertension at large referral centers.

Authors:  Meredith E Pugh; Anna R Hemnes; Aaron Trammell; John H Newman; Ivan M Robbins
Journal:  Pulm Circ       Date:  2014-12       Impact factor: 3.017

4.  Is it time to recognize a new phenotype? Heart failure with preserved ejection fraction with pulmonary vascular disease.

Authors:  Barry A Borlaug; Masaru Obokata
Journal:  Eur Heart J       Date:  2017-10-07       Impact factor: 29.983

Review 5.  Pulmonary Hypertension in Advanced Heart Failure: Assessment and Management of the Failing RV and LV.

Authors:  Sriram D Rao; Jonathan N Menachem; Edo Y Birati; Jeremy A Mazurek
Journal:  Curr Heart Fail Rep       Date:  2019-10

Review 6.  Pulmonary Hypertension in Heart Failure Patients: Pathophysiology and Prognostic Implications.

Authors:  Marco Guazzi; Valentina Labate
Journal:  Curr Heart Fail Rep       Date:  2016-12

Review 7.  Hemodynamics should be the primary approach to diagnosing, following, and managing pulmonary arterial hypertension.

Authors:  Bradley A Maron
Journal:  Can J Cardiol       Date:  2014-09-28       Impact factor: 5.223

8.  Challenges in Pulmonary Hypertension: Controversies in Treating the Tip of the Iceberg. A Joint National Institutes of Health Clinical Center and Pulmonary Hypertension Association Symposium Report.

Authors:  Jason M Elinoff; Richa Agarwal; Christopher F Barnett; Raymond L Benza; Michael J Cuttica; Ahmed M Gharib; Michael P Gray; Paul M Hassoun; Anna R Hemnes; Marc Humbert; Todd M Kolb; Tim Lahm; Jane A Leopold; Stephen C Mathai; Vallerie V McLaughlin; Ioana R Preston; Erika B Rosenzweig; Oksana A Shlobin; Virginia D Steen; Roham T Zamanian; Michael A Solomon
Journal:  Am J Respir Crit Care Med       Date:  2018-07-15       Impact factor: 21.405

Review 9.  Pulmonary arterial hypertension: pathogenesis and clinical management.

Authors:  Thenappan Thenappan; Mark L Ormiston; John J Ryan; Stephen L Archer
Journal:  BMJ       Date:  2018-03-14

10.  Features Associated With Discordance Between Pulmonary Arterial Wedge Pressure and Left Ventricular End Diastolic Pressure in Clinical Practice: Implications for Pulmonary Hypertension Classification.

Authors:  Anna R Hemnes; Alexander R Opotowsky; Tufik R Assad; Meng Xu; Laura N Doss; Eric Farber-Eger; Quinn S Wells; Evan L Brittain
Journal:  Chest       Date:  2018-08-24       Impact factor: 9.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.